EA031906B1 - Твердая пероральная лекарственная форма миртазапина и тизанидина для лечения болевого расстройства - Google Patents

Твердая пероральная лекарственная форма миртазапина и тизанидина для лечения болевого расстройства Download PDF

Info

Publication number
EA031906B1
EA031906B1 EA201591603A EA201591603A EA031906B1 EA 031906 B1 EA031906 B1 EA 031906B1 EA 201591603 A EA201591603 A EA 201591603A EA 201591603 A EA201591603 A EA 201591603A EA 031906 B1 EA031906 B1 EA 031906B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pain
mirtazapine
tizanidine
dosage form
solid oral
Prior art date
Application number
EA201591603A
Other languages
English (en)
Russian (ru)
Other versions
EA201591603A1 (ru
Inventor
Маргарита Алексеевна МОРОЗОВА
Аллан Герович БЕНИАШВИЛИ
Максим Эдуардович ЗАПОЛЬСКИЙ
Original Assignee
Общество С Ограниченной Ответственностью "Валента-Интеллект"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Валента-Интеллект" filed Critical Общество С Ограниченной Ответственностью "Валента-Интеллект"
Publication of EA201591603A1 publication Critical patent/EA201591603A1/ru
Publication of EA031906B1 publication Critical patent/EA031906B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201591603A 2013-03-22 2014-03-17 Твердая пероральная лекарственная форма миртазапина и тизанидина для лечения болевого расстройства EA031906B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2013112747/15A RU2509560C1 (ru) 2013-03-22 2013-03-22 Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
PCT/RU2014/000165 WO2014148951A1 (ru) 2013-03-22 2014-03-17 Новые терапевтические комбинации миртазапина для применения при болевых расстройствах

Publications (2)

Publication Number Publication Date
EA201591603A1 EA201591603A1 (ru) 2016-01-29
EA031906B1 true EA031906B1 (ru) 2019-03-29

Family

ID=50279596

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591603A EA031906B1 (ru) 2013-03-22 2014-03-17 Твердая пероральная лекарственная форма миртазапина и тизанидина для лечения болевого расстройства

Country Status (7)

Country Link
CN (1) CN105209044B (zh)
EA (1) EA031906B1 (zh)
HK (1) HK1214156A1 (zh)
MY (1) MY180772A (zh)
RU (1) RU2509560C1 (zh)
UA (1) UA112726C2 (zh)
WO (1) WO2014148951A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322116B2 (en) * 2014-01-21 2019-06-18 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
CN106243096B (zh) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
UA126916C2 (uk) * 2017-04-27 2023-02-22 Др. Редді'З Лабораторіз Лімітед Фармацевтична композиція кеторолаку
RU2736713C1 (ru) * 2019-12-02 2020-11-19 Общество С Ограниченной Ответственностью "Валента - Интеллект" Комбинация миртазапина и тизанидина для применения при болевых расстройствах

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080020076A1 (en) * 2006-07-21 2008-01-24 Khem Jhamandas Methods and Therapies for Potentiating a Therapeutic Action of an Alpha-2 Adrenergic Receptor Agonist and Inhibiting and/or Reversing Tolerance to Alpha-2 Adrenergic Receptor Agonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080020076A1 (en) * 2006-07-21 2008-01-24 Khem Jhamandas Methods and Therapies for Potentiating a Therapeutic Action of an Alpha-2 Adrenergic Receptor Agonist and Inhibiting and/or Reversing Tolerance to Alpha-2 Adrenergic Receptor Agonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KALIKSTA® (Calixta). Instruktsia po primeneniju, protivopokazania i sostav. Entsiklopedia RLS® № LP-001110 dated 03.11.2011 [on-line], [retrieved on 18.06.2014]. Found in Internet: <URL: http://www.rlsnet.ra/tn_index_id_50150.htm>, p. 1-3 *
SIRDALUD® (Sirdalud®). Instruktsia po primeneniju, protivopokazania i sostav. Entsiklopedia RLS® № PN012947/01 dated 03.08.2010 [on-line], [retrieved on 19.06.2014]. Found in Internet: <URL: http://www.rlsnet.ra/tn_index_id_2924.htm>, p. 1-7 *

Also Published As

Publication number Publication date
CN105209044A (zh) 2015-12-30
EA201591603A1 (ru) 2016-01-29
MY180772A (en) 2020-12-09
CN105209044B (zh) 2017-08-15
RU2509560C1 (ru) 2014-03-20
UA112726C2 (uk) 2016-10-10
HK1214156A1 (zh) 2016-07-22
WO2014148951A1 (ru) 2014-09-25

Similar Documents

Publication Publication Date Title
Mercadante et al. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study
JP4633262B2 (ja) 心的外傷後ストレス障害、強迫性障害および関連する神経精神医学的障害の処置
AU2002311784B8 (en) Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
EA006384B1 (ru) Композиция фентанила для интраназального введения
JP2016537322A (ja) Ｔｒｐａ１アンタゴニスト及び鎮痛剤を含む医薬組成物
RU2509560C1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
JP2016074728A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
JP6768520B2 (ja) 医療用の（ｓ）−ピルリンドールおよびその薬学的に許容可能な塩
JP7264813B2 (ja) 末梢神経障害性疼痛の治療に使用するための局所作用用フェニトイン
Khan et al. Effect of gabapentin on opioid requirements in patients undergoing total abdominal hysterectomy
AU2016303610A1 (en) Combination therapy using acamprosate and D-cycloserine
Keegan Muscle relaxants and neuromuscular blockade
US20060084659A1 (en) Augmentation of psychotherapy with cannabinoid reuptake inhibitors
Bufalari et al. Preemptive carprofen for peri-operative analgesia in dogs undergoing Tibial Plateau Leveling Osteotomy (TPLO): a prospective, randomized, blinded, placebo controlled clinical trial
EP2138174A1 (en) Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management
ES2649491T3 (es) (R)-pirlindol y sus sales farmacéuticamente aceptables para uso en medicina
CZ20021116A3 (cs) Synergické kombinace antagonisty receptoru NK1 a strukturálního analogu GABA
WO2005105120A2 (en) Pharmaceutical combination, active on central nervous system (cns) and set of pharmaceuticals; method of treatment of cns-disorders; means facilitating penetration of the hematoencephalic barrier; pharmaceutical means for endonasal administration
Visser et al. Salmon calcitonin in the treatment of post herpetic neuralgia
Chaudhary et al. Rationalized approach for the treatment of neuropathic pain
DOURADO et al. Treatment of chronic pain in dentistry using anticonvulsants
Saarma Trazodone—a review of literature
WO2008010768A1 (en) Method of treating and diagnosing restless legs syndrome and periodic limb movements during sleep and means for carrying out the method
BR112020016672A2 (pt) Leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma e método de reduzir, inibir ou eliminar um ou mais sintomas de síndrome das pernas inquietas (rls) em um indivíduo em necessidade do mesmo
BR112019022175A2 (pt) Composições e método para tratamento de depressão